Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis

Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis

Abstract Background Pegylated liposomal doxorubicin (PLD) and bevacizumab are commonly used to treat platinum-resistant ovarian cancer. While both agents are associated with cardiovascular toxicities, their combined impact on cardiotoxicity in real-world settings is not well defined. This study inve...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher W. Hoeger, Arrush Choudhary, Andrea Nathalie Rosas Diaz, Theresa Pinto, Sarah Smalec, Charles Doladille, Rishi Wadhera, Meghan Shea, Sumanth Khadke, Joe-Elie Salem, Sarju Ganatra, Aarti Asnani
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardio-Oncology
Subjects:
Pegylated liposomal doxorubicin
Bevacizumab
Cardiotoxicity
Heart failure
Ovarian cancer
Pharmacovigilance
Online Access:https://doi.org/10.1186/s40959-025-00351-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00351-4

Similar Items